Evidence map›Paper›PMID 42064045›Full record

ArticleFrontiers in immunology2026

An agent-based learning model integrating sex differences in renal cell carcinoma.

Emanuela Merelli, Tarek Taha, Marco Caputo, Destiny Obude, Edoardo Papa, Alessandro Rizzo, Sebastiano Buti, Francesco Massari, Javier Molina-Cerrillo, Fernando Sabino Marques Monteiro and 2 more

Abstract read
In one paragraph

Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Emanuela MerelliSchool of Sciences and Technology, University of Camerino, Camerino, MC, Italy.
Tarek TahaRoyal Marsden NHS Foundation Trust, London, United Kingdom.
Marco CaputoSchool of Sciences and Technology, University of Camerino, Camerino, MC, Italy.
Destiny ObudeSchool of Sciences and Technology, University of Camerino, Camerino, MC, Italy.
Edoardo PapaSchool of Sciences and Technology, University of Camerino, Camerino, MC, Italy.
Alessandro RizzoIstituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Istituto Tumori "Giovanni Paolo II", Bari, Italy.
Sebastiano ButiMedical Oncology Unit, University Hospital of Parma, Parma, Italy.
Francesco MassariMedical Oncology, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
Javier Molina-CerrilloDepartment of Medical Oncology, Hospital Ramón y Cajal, Madrid, Spain.
Fernando Sabino Marques MonteiroLatin American Cooperative Oncology Group - LACOG, Porto Alegre, Brazil.
Brigida Anna MaioranoDepartment of Medical Oncology, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) San Raffaele Hospital, Milan, Italy.
Matteo SantoniARON Research Foundation Ente del Terzo Settore (ETS), Macerata, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Sex-based differences influence tumor biology, immune responses, and treatment outcomes in renal cell carcinoma (RCC), yet most computational models do not jointly incorporate sex hormones, immune composition, and tumor genetic evolution. Agent-based models (ABMs) effectively simulate tumor-immune interactions but are rarely extended to include sex-specific modulation or machine learning-based optimization. This study enhanced an agent-based learning model (ALM) to simulate RCC progression and treatment response by integrating hormonal effects, immune interactions, and tumor genetic adaptation with data-driven tuning. Methods: An RCC-specific ALM was developed incorporating immune agents (CD8+, NK, Treg, dendritic cells), hormone-sensitive mechanisms, tumor genetic modules, and effects of immune checkpoint inhibitors ( Results: Simulations reproduced sex-specific treatment responses. Female models showed delayed initial responses but stronger late immune activation and rapid tumor regression, whereas male models exhibited more stable early responses but greater tumor resilience driven by genetic adaptations. Adaptive learning showed capability of reducing prediction error with both fitness functions. Conclusions: This ALM offers an exploratory framework to provide preliminary insights into how sex hormones, immune dynamics, and tumor genetics may jointly contribute to shaping RCC treatment outcomes. Although the limited sample size constrains validation, the results suggest the potential of combining ABMs with biological data-driven optimization to support patient prediction and call for further investigation in larger cohorts.

Indexed as

Carcinoma, Renal CellKidney NeoplasmsMachine LearningComputer SimulationFemaleHumansImmune Checkpoint InhibitorsMaleSex CharacteristicsSex FactorsImmune Checkpoint InhibitorsAgent-Based Model (ABM)Agent-Learning Model (ALM)computational simulationimmune system responseimmunotherapymachine learningRCC

Identifiers

PMID42064045
PMCPMC13126258

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.